JP2023520047A5 - - Google Patents

Info

Publication number
JP2023520047A5
JP2023520047A5 JP2022559873A JP2022559873A JP2023520047A5 JP 2023520047 A5 JP2023520047 A5 JP 2023520047A5 JP 2022559873 A JP2022559873 A JP 2022559873A JP 2022559873 A JP2022559873 A JP 2022559873A JP 2023520047 A5 JP2023520047 A5 JP 2023520047A5
Authority
JP
Japan
Application number
JP2022559873A
Other languages
Japanese (ja)
Other versions
JP7791103B2 (ja
JPWO2021202694A5 (https=
JP2023520047A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025128 external-priority patent/WO2021202694A1/en
Publication of JP2023520047A publication Critical patent/JP2023520047A/ja
Publication of JP2023520047A5 publication Critical patent/JP2023520047A5/ja
Publication of JPWO2021202694A5 publication Critical patent/JPWO2021202694A5/ja
Priority to JP2025244099A priority Critical patent/JP2026048786A/ja
Application granted granted Critical
Publication of JP7791103B2 publication Critical patent/JP7791103B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022559873A 2020-04-01 2021-03-31 フェノール酸脂質系カチオン性脂質 Active JP7791103B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025244099A JP2026048786A (ja) 2020-04-01 2025-12-10 フェノール酸脂質系カチオン性脂質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003698P 2020-04-01 2020-04-01
US63/003,698 2020-04-01
PCT/US2021/025128 WO2021202694A1 (en) 2020-04-01 2021-03-31 Phenolic acid lipid based cationic lipids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025244099A Division JP2026048786A (ja) 2020-04-01 2025-12-10 フェノール酸脂質系カチオン性脂質

Publications (4)

Publication Number Publication Date
JP2023520047A JP2023520047A (ja) 2023-05-15
JP2023520047A5 true JP2023520047A5 (https=) 2024-04-11
JPWO2021202694A5 JPWO2021202694A5 (https=) 2024-04-11
JP7791103B2 JP7791103B2 (ja) 2025-12-23

Family

ID=75625666

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022559873A Active JP7791103B2 (ja) 2020-04-01 2021-03-31 フェノール酸脂質系カチオン性脂質
JP2025244099A Pending JP2026048786A (ja) 2020-04-01 2025-12-10 フェノール酸脂質系カチオン性脂質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025244099A Pending JP2026048786A (ja) 2020-04-01 2025-12-10 フェノール酸脂質系カチオン性脂質

Country Status (4)

Country Link
EP (1) EP4126813A1 (https=)
JP (2) JP7791103B2 (https=)
CN (2) CN121318756A (https=)
WO (1) WO2021202694A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4313115A1 (en) 2021-03-25 2024-02-07 Translate Bio, Inc. Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
US20250073351A1 (en) * 2021-04-19 2025-03-06 Translate Bio, Inc. Improved compositions for delivery of mrna
MX2024002726A (es) 2021-09-03 2024-03-20 CureVac SE Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos.
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024133515A1 (en) 2022-12-20 2024-06-27 Sanofi Rhinovirus mrna vaccine
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2025189064A1 (en) 2024-03-08 2025-09-12 Genzyme Corporation Lipid nanoparticles
WO2026003373A1 (en) 2024-06-28 2026-01-02 Sanofi Phenolic acid lipid based cationic lipids
WO2026008743A1 (en) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US6472397B1 (en) * 1998-04-09 2002-10-29 Meiji Seika Kaisha, Ltd. Nitrogen-containing heterocyclic compounds having antiplatelet aggregation effect and medicinal use thereof
JP6557722B2 (ja) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための生分解性脂質
HRP20220652T1 (hr) * 2015-12-10 2022-06-24 Modernatx, Inc. Pripravci i postupci unosa terapijskih sredstava
MA45032A (fr) 2016-05-18 2019-03-27 Fundacion Para La Investig Medica Aplicada Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë
WO2018089801A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
SMT202300097T1 (it) 2017-03-15 2023-05-12 Modernatx Inc Composto e composizioni per il rilascio intracellulare di agenti terapeutici
CN112437767B (zh) * 2018-05-24 2023-10-27 川斯勒佰尔公司 硫酯阳离子脂质
EP3849617A1 (en) * 2018-09-14 2021-07-21 Translate Bio, Inc. Composition and methods for treatment of methylmalonic acidemia
CN110526885A (zh) * 2019-08-20 2019-12-03 上海英诺富成生物科技有限公司 麦考酚酸的前体药物及其制备方法

Similar Documents

Publication Publication Date Title
JP2023520047A5 (https=)
BR102021016176A2 (https=)
CN305979960S (https=)
CN305881414S (https=)
CN305929372S (https=)
CN305914463S (https=)
CN305913675S (https=)
CN305912522S (https=)
CN305910447S (https=)
CN305909104S (https=)
CN305908046S (https=)
CN305904461S (https=)
CN305536656S (https=)
CN305536489S (https=)
CN305535695S (https=)
CN305534824S (https=)
CN305534132S (https=)
CN305534002S (https=)
CN305978054S (https=)
CN305903990S (https=)
CN305533577S (https=)
CN305533558S (https=)
CN305533107S (https=)
CN305532852S (https=)
CN305532335S (https=)